Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

SonaCare Medical highlights need for image-guided technologies to better identify prostate cancer

The need to add tissue preserving therapies to the prostate cancer treatment continuum was highlighted prominently at the 108th Annual Meeting of the American Urological Association, in San Diego.

24 May 2013

Cenix BioScience, Debiopharm partner to develop novel therapeutic drug candidates

Cenix BioScience, a leading preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that they have signed a research agreement to support Debiopharm in its ongoing efforts to develop novel therapeutic drug candidates.

23 May 2013

OncoGenex plans to initiate OGX-42 Phase 2 trial in patients with advanced squamous cell lung cancer

OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.

23 May 2013

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.

23 May 2013

Study identifies specific genetic factors that influence occurrence and severity of sepsis

A study published in the June issue of Anesthesiology represents an important first step in establishing new therapeutic options targeting specific genetic areas that influence the occurrence and severity of sepsis - a life-threatening, whole-body response to infection.

23 May 2013

Mayo Clinic, Cancer Genetics form joint venture to improve cancer care

Mayo Clinic and Cancer Genetics Inc. today launched OncoSpire Genomics, a joint venture with the singular goal of improving cancer care by discovering and commercializing diagnostic tests that leverage next-generation sequencing.

23 May 2013

Cancer experts to discuss latest developments and implications of cell therapies in oncology

John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 cancer centers, will bring together leading cancer experts, for presentation and discussion of the latest developments and implications of cell therapy and interventional immunology in oncology, on Friday, June 7 from 7:00am to 1:30pm.

23 May 2013

Researchers create radioactive nanoparticles that target lymphoma tumor cells

Cancers of all types become most deadly when they metastasize and spread tumors throughout the body. Once cancer has reached this stage, it becomes very difficult for doctors to locate and treat the numerous tumors that can develop.

22 May 2013

RyMed's InVision-Plus neutral connector reduces CRBSIs by 33.3% at Johns Hopkins center

Research on different types of IV connectors led a Johns Hopkins cancer center to pilot a "neutral pressure" IV connector, according to a scientific presentation at the annual meeting of the Oncology Nursing Society.

22 May 2013

Naloxegol meets primary and secondary endpoints in two pivotal Phase III studies

AstraZeneca today presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies.

22 May 2013

Obesity directly tied to several cancers

"Obesity is a major risk factor for developing cancer, roughly the equivalent of tobacco use, and both are potentially reversible. Further, obese cancer patients do worse in surgery, with radiation or on chemotherapy - worse by any measure." Karen Basen-Engquist, Ph.D., Director of MD Anderson's new Center for Energy Balance in Cancer Prevention and Survivorship and professor of Behavioral Science.

22 May 2013

Research suggests that IMRT may not be more effective in patients who had prostatectomy

Intensity-modulated radiation therapy has become the most commonly used type of radiation in prostate cancer, but research from the University of North Carolina suggests that the therapy may not be more effective than older, less expensive forms of radiation therapy in patients who have had a prostatectomy.

22 May 2013

Poliovirus vaccine study shows encouraging results in glioblastoma patients

An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.

22 May 2013

PGDx to identify novel kinase targets in collaboration with Blueprint Medicines

Personal Genome Diagnostics Inc., today announced that it will use its proprietary methodologies and expertise in genomic analysis of defined cancer subtypes to identify novel kinase targets in collaboration with Blueprint Medicines.

21 May 2013

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy.

From Pfizer, Inc. 21 May 2013

Researchers develop new mouse model to discover gene pathways that drive MPNST

University of Minnesota Medical School researchers from the Masonic Cancer Center, University of Minnesota, in partnership with the University's Brain Tumor Program, have developed a new mouse model of malignant peripheral nerve sheath tumors that allow them to discover new genes and gene pathways driving this type of cancer.

21 May 2013

GE Healthcare initiates global public awareness campaign on cancer prevention

GE Healthcare has today launched its third annual #GetFit global public awareness campaign on cancer prevention. This year's campaign leverages social media channels including Instagram, Sina Weibo in China, and Twitter to enable participation, interaction and engagement.

20 May 2013

Cell Therapeutics announces issuance of final benefit assessment report for PIXUVRI

Cell Therapeutics, Inc. today reported that Germany's Federal Joint Committee has issued its final benefit assessment report for PIXUVRI (pixantrone), which is indicated as a monotherapy for the treatment of adult patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have failed two or three prior lines of therapy.

20 May 2013

Measuring genetic diversity within tumor predicts outcomes of patients with head and neck cancer

A new measure of the heterogeneity - the variety of genetic mutations - of cells within a tumor appears to predict treatment outcomes of patients with the most common type of head and neck cancer.

20 May 2013

Targeting glucagon action: A new frontier for regulating diabetes

For the first time, scientists at the Toronto General Research Institute showed that targeting glucagon action in the brain may be a new frontier for regulating diabetes.

20 May 2013

Oncology News and Research

Further Reading

SonaCare Medical highlights need for image-guided technologies to better identify prostate cancer

Cenix BioScience, Debiopharm partner to develop novel therapeutic drug candidates

OncoGenex plans to initiate OGX-42 Phase 2 trial in patients with advanced squamous cell lung cancer

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

Study identifies specific genetic factors that influence occurrence and severity of sepsis

Mayo Clinic, Cancer Genetics form joint venture to improve cancer care

Cancer experts to discuss latest developments and implications of cell therapies in oncology

Researchers create radioactive nanoparticles that target lymphoma tumor cells

RyMed's InVision-Plus neutral connector reduces CRBSIs by 33.3% at Johns Hopkins center

Naloxegol meets primary and secondary endpoints in two pivotal Phase III studies

Obesity directly tied to several cancers

Research suggests that IMRT may not be more effective in patients who had prostatectomy

Poliovirus vaccine study shows encouraging results in glioblastoma patients

PGDx to identify novel kinase targets in collaboration with Blueprint Medicines

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

Researchers develop new mouse model to discover gene pathways that drive MPNST

GE Healthcare initiates global public awareness campaign on cancer prevention

Cell Therapeutics announces issuance of final benefit assessment report for PIXUVRI

Measuring genetic diversity within tumor predicts outcomes of patients with head and neck cancer

Targeting glucagon action: A new frontier for regulating diabetes

eBook: Liquid biopsy in cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News